Recombinant canstatin inhibits angiopoietin-1-induced angiogenesis and lymphangiogenesis

International Journal of Cancer

Volumn 131, Issue 2, 2012, Pages 298-309

  Hwang Bo, Jeon ^a   Yoo, Ki Hyun ^a   Park, Jong Hwa ^a   Jeong, Han Sin ^b   Chung, In Sik ^a  

^a Kyung Hee University   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

angiopoietin 1; CT 26 colon carcinoma animal model; human umbilical vein endothelial cell; lymphatic endothelial cell; recombinant canstatin

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN RECEPTOR; CANSTATIN; RECOMBINANT CANSTATIN; UNCLASSIFIED DRUG; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL DENSITY; COLON CARCINOMA; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; MALE; MIGRATION INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR VOLUME; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

ANGIOPOIETIN-1; ANIMALS; CELL HYPOXIA; CELL MOVEMENT; CELL PROLIFERATION; COLLAGEN TYPE IV; ENDOTHELIAL CELLS; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LYMPHANGIOGENESIS; MALE; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTOR PROTEIN-TYROSINE KINASES; RECOMBINANT PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84861626294     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26353     Document Type: Article

References (31)

1. Folkman J,. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
2. Boedefeld WM, Bland KI, Heslin MJ,. Recent insight into angiogenesis, apoptosis, invasion, and metastasis in colorectal carcinoma. Ann Surg Oncol 2003; 10: 839-51.
3. Mundal TM, Kalluri R,. Type IV collagen-derived angiogenesis inhibitors. Microvas Res 2007; 74: 85-9.
4. Semenza GL,. Angiogenesis in ischemic and neoplastic disorders. Annu Rev Med 2003; 54: 17-28.
5. Alitalo K, Carmeliet P,. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 2002; 1: 219-77.
6. Achen MG, Stacker SA,. Tumor lymphangiogenesis and metastatic spread - new players begin to emerge. Int J Cancer 2006; 119: 1755-60.
7. McColl BK, Loughran SJ, Davydova N, Stacker SA, Achen MG,. Mechanisms of lymphangiogenesis: targets for blocking the metastatic spread of cancer. Curr Cancer Drug Targets 2005; 5: 561-71.
8. Da MX, Wu Z, Tian HW,. Tumor lymphangiogenesis and lymphangiogenic growth factors. Arch Med Res 2008; 39: 365-72.
9. Ji RC,. Lymph node lymphangiogenesis: a new concept for modulating tumor metastasis and inflammatory process. Histol Histopathol 2009; 24: 377-84.
10. Kamphaus GD, Colorado PC, Panka DJ, Hopfer H, Ramchandran R, Torre A, Maeshima Y, Mier JW, Sukhatme VP, Kalluri R,. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 2000; 275: 1209-15.
11. He GA, Luo JX, Zhang TY, Hu ZH, Wang FY,. The C-terminal domain of canstatin suppresses in vivo tumor growth associated with proliferation of endothelial cells. Biochem Biophys Res Commun 2004; 318: 354-60.
12. Panka DJ, Mier JW,. Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in endothelial cells. J Biol Chem 2003; 278: 37632-6.
13. He XP, Li ZS, Zhu RM, Tu ZX, Gao J, Pan X, Gong YF, Jin J, Man XH, Wu HY, Xu AF,. Effects of recombinant human canstatin protein in the treatment of pancreatic cancer. World J Gastroenterol 2006; 12: 6652-7.
14. Wang WB, Zhou YL, Heng DF, Miao CH, Cao YL,. Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and canstatin gene suppression therapy on breast tumor xenograft growth in mice. Breast Cancer Res Treat 2008; 110: 283-95.
15. Li YY, Qian GS, Haung GJ, Chen F, Qian P, Yu SC, Wang CZ, Li Q, Wang JC, Wu GM,. Enhancement of antiangiogenic effects of human canstatin with a hypoxia-regulated transgene vector in lung cancer model. Cancer J 2006; 12: 136-46.
16. Hwang-Bo J, Yoo KH, Jeong HS, Chung IS,. Recombinant canstatin inhibits tumor growth in an orthotoic AT-84 oral squamous cell carcinoma model. Biotechnol Lett 2010; 32: 189-94.
17. Lee JM, Hwang-Bo J, Shon BH, Chung IS,. Functional expression of recombinant canstatin in stably transformed Drosophila melanogaster S2 cells. Protein Expr Purif 2007; 52: 258-64.
18. Alessandria G, Filippeschi S, Sinibaldi P, Mornet F, Passera P, Spreafico F, Cappa PM, Gullino PM,. Influence of gangliosides on primary and metastatic neoplastic growth in human and murine cells. Cancer Res 1987; 47: 4243-7.
19. 2-induced hypoxia. Nitric Oxide 2010; 23: 234-41.
20. Huang Y, Du KM, Xue ZH, Yan H, Li D, Liu W, Chen Z, Zhao Q, Tong JH, Zhu YS, Chen GQ,. Cobalt chloride an low oxygen tension trigger differentiation of acute myeloid leukemic cells: possible mediation of hypoxia-inducible factor-1α. Leukemia 2003; 17: 2065-73.
21. An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV, Neckers LM,. Stabilization of wild-type p53 by hypoxia-inducible factor 1α. Nature 1998; 392: 405-8.
22. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD,. Requisite role of angiopoietin-1, a ligand for TIE2 receptor, during embryonic angiogenesis. Cell 1996; 87: 1171-80.
23. Fukuhara S, Sako K, Noda K, Xhang J, Minami M, Mochizuki N,. Angiopoietin-1/Tie2 receptor signaling in vascular quiescence and angiogenesis. Histol Histopathol 2010; 25: 387-96.
24. Wu X, Liu N,. The role of Ang/Tie signaling in lymphangiogenesis. Lymphology 2010; 43: 59-72.
25. Hynes RO,. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110: 673-87.
26. Garmy-Susini B, Varmer JA,. Roles of integrins in tumor angiogenesis and lymphangiogenesis. Lymphat Res Biol 2008; 6: 155-63.
27. Brooks PC, Clark RA, Cheresh DA,. Requirement of vascular integrin αv β3 for angiogenesis. Science 1994; 264: 569-71.
28. Magnon C, Galaup A, Mullan B, Rouffiac V, Bidart JM, Friscelli F, Opolon P, Perricaudet M,. Canstatin acts on endothelial and tumor cells via mitochondrial damage initiated through interaction with αvβ3 and αvβ5 integrins. Cancer Res 2005; 15: 4353-61.
29. Hong YK, Lange-Asschenfeldt B, Velasco P, Hirakawa S, Kunsfeld R, Brown LF, Bohlen P, Senger DR, Detmar M,. VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the α1β1 and α2β1 integrins. FASEB J 2004; 18: 1111-13.
30. Garmy-Sumini B, Makale M, Fuster M, Varner JA,. Methods to study lymphatic vessel integrins. Methods Enzymol 2007; 426: 415-38.
31. Tammela T, Saaristo A, Lohela M, Morisada T, Tornberg J, Norrmen C, Oike Y, Pajusola K, Thurston G, Suda T, Yla-Herttuala S, Alitalo K,. Angiopoietin-1 promotes lymphatic sprouting and hyperplasis. Blood 2005; 105: 4642-8.